Related Experiment Videos

Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD

Lin Xu1, Chao Qiang Jiang, Tai Hing Lam

  • 1Department of Community Medicine, School of Public Health, University of Hong Kong, Hong Kong, China.

Clinical Endocrinology
|December 7, 2010
PubMed

Insights

Elevated plasminogen activator inhibitor-1 (PAI-1) levels are linked to prediabetes and impaired glucose metabolism in older Chinese adults. This suggests a higher risk for future diabetes and cardiovascular disease development.

Area of Science:

  • Endocrinology
  • Metabolic Syndrome
  • Cardiovascular Risk Factors

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis.
  • Elevated PAI-1 levels are associated with obesity, insulin resistance, and cardiovascular disease.
  • The relationship between PAI-1 and early stages of glucose dysregulation requires further investigation.

Purpose of the Study:

  • To investigate the association between plasma plasminogen activator inhibitor-1 (PAI-1) levels and diabetes status in older Chinese adults.
  • To identify potential biomarkers for early detection of glucose metabolism abnormalities.

Main Methods:

  • A cross-sectional study of 1,393 older Chinese individuals from the Guangzhou Biobank Cohort Study.
  • Diabetes status was categorized using American Diabetes Association criteria (2010), including impaired HbA1c (IA1c), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes.
  • Plasma PAI-1 levels were measured and compared across different glucose metabolism groups after adjusting for confounders.

Main Results:

  • Individuals with IA1c (5.7-6.4% HbA1c) and IFG/IGT exhibited significantly higher plasma PAI-1 levels compared to normoglycemic individuals.
  • Adjusted mean differences in PAI-1 were 32.0 ng/ml (IA1c) and 33.3 ng/ml (IFG/IGT) (P<0.01).
  • These groups also showed adverse levels of other vascular risk factors.

Conclusions:

  • Increased plasma PAI-1 levels are associated with early glucose dysregulation, specifically IA1c and IFG/IGT, in older Chinese adults.
  • These findings suggest that PAI-1 may serve as an early indicator of increased risk for future diabetes.
  • Elevated PAI-1 in these prediabetic states may also signify an increased risk for cardiovascular diseases.
Abstract

Related Concept Videos

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...